Search research articles
Contact Us
Filters
Showing results (271-280 of 305) with videos related to
Page
of 31
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
L Pusztai, C Denkert, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
J Cortes, V Calvo, N Ramírez-Merino, et al.
Autophagy
|
December 16, 2016
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression
Alicia M Blessing, Kimal Rajapakshe, Lakshmi Reddy Bollu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2011
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
J Cortes, V Calvo, N Ramírez-Merino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
E Vrdoljak, N Marschner, C Zielinski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2018
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D A Yardley, R Coleman, P Conte, et al.
Leukemia
|
September 23, 2016
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M H Qazilbash, E Wieder, P F Thall, et al.
Geroscience
|
August 29, 2025
From dark horse to front-runner: vascular contributions to brain health : Proceedings of the 2022 annual workshop of the Albert research institute for white matter and cognition
Aditi Gupta, Paulo W Pires, Sandra A Billinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2017
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
P Jain, E Aoki, M Keating, et al.
Leukemia
|
July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Page
of 31
Search research articles
Search
Showing results (271-280 of 305) with videos related to
Sort By:
Page
of 31
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
L Pusztai, C Denkert, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
J Cortes, V Calvo, N Ramírez-Merino, et al.
Autophagy
|
December 16, 2016
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression
Alicia M Blessing, Kimal Rajapakshe, Lakshmi Reddy Bollu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2011
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
J Cortes, V Calvo, N Ramírez-Merino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
E Vrdoljak, N Marschner, C Zielinski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2018
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D A Yardley, R Coleman, P Conte, et al.
Leukemia
|
September 23, 2016
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M H Qazilbash, E Wieder, P F Thall, et al.
Geroscience
|
August 29, 2025
From dark horse to front-runner: vascular contributions to brain health : Proceedings of the 2022 annual workshop of the Albert research institute for white matter and cognition
Aditi Gupta, Paulo W Pires, Sandra A Billinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2017
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
P Jain, E Aoki, M Keating, et al.
Leukemia
|
July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Page
of 31